|  |  |
| --- | --- |
|  | **NHS Prescription Services**  Bridge House  152 Pilgrim Street  Newcastle upon Tyne  NE1 6SN  0845 850 0001  Email:[nhsbsa.prescriptionservices@nhsbsa.nhs.uk](mailto:nhsbsa.prescriptionservices@nhsbsa.nhs.uk)  Website:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  17 Mar 2025 |
|  |

VERSION 3.2.0

Dear dm+d User,

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

The recent work to add the ingredients to Virtual Therapeutic Moieties (VTMs) that needed populating has been completed.

The [dm+d Editorial Policy](https://www.nhsbsa.nhs.uk/pharmacies-gp-practices-and-appliance-contractors/dictionary-medicines-and-devices-dmd) has now been updated to reflect the latest policy and will continue to be updated as-and-when any other exclusions are identified

**Please note that VTM Ingredients information will only be available via TRUD and the NHS England Terminology Server from 23 September 2024 and will not be seen in the dm+d browser until further notice is provided.**

Additional information about the change is available on the following [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ukmeds@nhs.net)

**Survey: dm+d and SNOMED CT UK Drug Extension release cycles**

We are providing an update regarding the [user survey for dm+d and SNOMED CT UK Drug Extension release cycles](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/survey-dm-d-and-snomed-ct-uk-drug-extension-release-cycles) which ran from 11 November to 6 December 2024.

The purpose of the survey was to seek viewsfrom users of dm+d and/or SNOMED CT UK Drug Extension data, to understand preferences for release timings of the two terminologies and potential impacts if they were changed.

Firstly, thank you to everyone who submitted a response and for providing your views.

NHS England has analysed the survey responses. A summary of the findings are:

* Based on user preferences, the release timings of both dm+d and SNOMED CT UK Drug Extension will remain at their current frequencies
* There is strong interest from users to access a ‘live data feed’ ([NHS England Terminology Server](https://digital.nhs.uk/services/terminology-server)) to provide greater alignment and ‘real-time’ data between terminologies and release cycles. NHS England will undertake further engagement to understand what information users need to help them make an informed decision
* A small number of users have requested an additional dedicated Drug Tariff dm+d release to the current weekly releases for the end of each month to support their Drug Tariff data processing. NHS England will undertake further work to understand the feasibility of delivering this

Further information will be shared once available.

If you would like to discuss this work further, contact [nhsdigital.ukmeds@nhs.net](mailto:nhsdigital.ukmeds@nhs.net)

**SNOMED International Proposal to Increase Description Length Limit**

We are providing an update to the [information previously communicated](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) regarding the proposal from SNOMED International to increase the maximum length of Fully Specified Name and Synonym descriptions,.

SNOMED International have provided [further information](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1154361&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) about the [proposal to increase description length limit](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1108441&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) from 255 to 4096 characters.

NHS England are currently assessing whether this proposed change will impact Fully Specified Names (FSN) created in the SNOMED CT UK Drug Extension. NHS England do not expect that this proposed change will impact Preferred Terms (PT) in the SNOMED CT UK Drug Extension.

This proposal will impact UK users of the **Medicinal Product Hierarchy of the SNOMED International Edition** (both SNOMED CT International Edition and SNOMED CT UK Edition) but dm+d will NOT be affected and we have no plans to adopt these changes.

The planned implementation date for **SNOMED International** **changes is January 2026** and will come into effect in the **April 2026 UK release**.

Any concerns or queries should be directed to SNOMED International at [release@snomed.org](mailto:release@snomed.org). Please cc [information.standards@nhs.net](mailto:information.standards@nhs.net) to enable NHS England to have visibility of UK stakeholder feedback.

**Monthly dm+d Supplier Workshop**

NHS England hosts a monthly workshop for IT system suppliers to discuss dm+d content and implementation queries.  It is an opportunity to speak with colleagues from NHS England and the NHSBSA who manage the terminology.

If you are a system supplier who is interested in joining the group, please contact [medicinestandards@nhs.net](mailto:medicinestandards@nhs.net) for more information.

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |  |  |  |
| --- | --- | --- | --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** | | | |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported | 14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order | 21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported | 27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported | 27/03/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) | 27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) | 27/11/2023 |
| Hydrogen peroxide 3% solution | 42510811000001109 | Imported | 18/12/2023 |
| Creon 10000 capsules | 43034611000001101 | Imported | 15/07/2024 |
| Creon 25000 capsules | 43034811000001102 | Imported | 15/07/2024 |
| Pancreaze Delayed-Release capsules | 43035111000001108 | Imported | 15/07/2024 |
| Ipratropium bromide 250micrograms/1ml nebuliser liquid unit dose vials | 43093511000001105 | Imported | 22/07/2024 |
| Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials | 43094411000001109 | Imported | 22/07/2024 |
| Methylphenidate 18mg modified-release tablets | 43210911000001100 | Imported | 02/09/2024 |
| Methylphenidate 27mg modified-release tablets | 43211511000001100 | Imported | 02/09/2024 |
| Methylphenidate 36mg modified-release tablets | 43211911000001107 | Imported | 02/09/2024 |
| Methylphenidate 54mg modified-release tablets | 43212411000001109 | Imported | 02/09/2024 |
| Pangrol 10,000 capsules | 43788211000001100 | Imported | 23/09/2024 |
| Pangrol 25,000 capsules | 43788511000001102 | Imported | 23/09/2024 |
| Imiquimod 5% cream 250mg sachets | 41526711000001106 | Imported | 02/12/2024 |
| Quetiapine 50mg modified-release tablets | 44616911000001103 | Imported | 17/02/2025 |
| Quetiapine 150mg modified-release tablets | 44617411000001108 | Imported | 17/02/2025 |
| Quetiapine 200mg modified-release tablets | 44617711000001102 | Imported | 17/02/2025 |
| Quetiapine 300mg modified-release tablets | 44618011000001103 | Imported | 17/02/2025 |
| Quetiapine 400mg modified-release tablets | 44618311000001100 | Imported | 17/02/2025 |
| Fluorouracil 5% cream | 44618611000001105 | Imported | 17/02/2025 |
| Imiquimod 3.75% cream 250mg sachets | 44618911000001104 | Imported | 17/02/2025 |
| Sodium fusidate 250mg tablets | 44619211000001103 | Imported | 17/02/2025 |
| Fusidic acid 250mg/5ml oral suspension | 44619511000001100 | Special Order | 17/02/2025 |
| Desmopressin 10micrograms/dose nasal spray | 44920311000001108 | Imported | 17/03/2025 |
| Flucytosine 500mg capsules | 44920711000001107 | Imported | 17/03/2025 |
| Diazepam 2mg/5ml oral suspension | 19674911000001101 | Special Order | 17/03/2025 |

**Invalidation****s**

None

**Advance Notice of Invalidations**

The following concept will be invalidated mid-March as it was added erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Amikacin 500mg/2ml solution for injection vials (not to be made invalid) | **VMP** Amikacin 500mg/2ml solution for injection ampoules |
| **VMP SNOMED ID** 35899911000001109 | **VMP SNOMED ID**  44422511000001103 |
| **VMPP** 5 vials (not to be made invalid) | **VMPP** 5 ampoule |
| **VMPP SNOMED ID** 4500011000001105 | **VMPP SNOMED ID** 44374911000001108 |
| **AMP** Amikacin 500mg/2ml solution for injection vials (Kent Pharma (UK) Ltd) | **AMP** Amikacin 500mg/2ml solution for injection ampoules (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**  42788511000001107 | **AMP SNOMED ID** 44375011000001108 |
| **AMPP** 5 vials | **AMPP** 5 ampoule |
| **AMPP SNOMED ID** 42788611000001106 | **AMPP SNOMED ID** 44375111000001109 |

The following concepts will be invalidated mid-April. Following correspondence from Torrent Pharma (UK) Ltd, these concepts have had to be invalidated and in-line with dm+d Editorial Policy invalidation criteria, this is labelled with the ‘erroneous’ reason code.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Lenalidomide 2.5mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 23344511000001104 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 23307311000001107 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 2.5mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40655111000001104 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40655211000001105 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Lenalidomide 5mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 41765111000001109 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 11755111000001102 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 5mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40656611000001102 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40656711000001106 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Lenalidomide 7.5mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 29903811000001104 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 29894711000001101 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 7.5mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40656811000001103 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40657011000001107 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP** Lenalidomide 10mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 41765011000001108 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 11755611000001105 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 10mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40654711000001102 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40654811000001105 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **VMP** Lenalidomide 15mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 11762911000001102 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 11755911000001104 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 15mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40654911000001100 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40655011000001100 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **VMP** Lenalidomide 20mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 29903711000001107 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 29895311000001101 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 20mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40655311000001102 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40655411000001109 | **AMPP SNOMED ID** N/A |

|  |  |
| --- | --- |
| **VMP** Lenalidomide 25mg capsules (VMP not to be made invalid) | **VMP** N/A |
| **VMP SNOMED ID** 11763011000001105 | **VMP SNOMED ID**  N/A |
| **VMPP** 21 (VMPP not to be made invalid) | **VMPP** N/A |
| **VMPP SNOMED ID** 11756311000001105 | **VMPP SNOMED ID** N/A |
| **AMP**  Lenalidomide 25mg capsules (Torrent Pharma (UK) Ltd) | **AMP** N/A |
| **AMP SNOMED ID**  40656411000001100 | **AMP SNOMED ID N/A** |
| **AMPP** 21 capsule | **AMPP** N/A |
| **AMPP SNOMED ID** 40656511000001101 | **AMPP SNOMED ID** N/A |

dm+d Authoring Team